entinostat has been researched along with Epithelial Ovarian Cancer in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is an immunoreactive subtype of ovarian cancer with a favorable prognosis, but the majority of ovarian cancers have limited immune reactivity." | 1.62 | Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition. ( Anderson, L; Chen, HW; Fejzo, MS; Karlan, B; Konecny, GE; McDermott, MS; Slamon, DJ, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fejzo, MS | 1 |
| Chen, HW | 1 |
| Anderson, L | 1 |
| McDermott, MS | 1 |
| Karlan, B | 1 |
| Konecny, GE | 1 |
| Slamon, DJ | 1 |
| Gupta, VG | 1 |
| Hirst, J | 1 |
| Petersen, S | 1 |
| Roby, KF | 1 |
| Kusch, M | 1 |
| Zhou, H | 1 |
| Clive, ML | 1 |
| Jewell, A | 1 |
| Pathak, HB | 1 |
| Godwin, AK | 1 |
| Wilson, AJ | 1 |
| Crispens, MA | 1 |
| Cybulla, E | 1 |
| Vindigni, A | 1 |
| Fuh, KC | 1 |
| Khabele, D | 1 |
2 other studies available for entinostat and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bi | 2021 |
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; BRCA1 Protein; Carcinoma, Ovari | 2021 |